20 results on '"A. Arín"'
Search Results
2. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
3. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib
4. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers
5. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
6. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
7. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
8. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
9. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study
10. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
11. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4 + T cell responses in endometrial cancer patients
12. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
13. A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study
14. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer
15. The significance of perineural invasion in early-stage cervical cancer
16. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
17. Early stage uterine serous carcinoma: Does surgical approach impact survival?
18. Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo
19. Robotic resection of bulky aorto-caval lymphadenopathy in a patient with serous fallopian tube carcinoma
20. Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.